A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
About Sunshine Biopharma We are a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. We have two wholly owned subsidiaries: (i) Nora Pharma Inc. (“Nora Pharma”), a Canadian corporation, through which we currently have 70 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. (“Sunshine Canada”), a Canadian corporation which develops and sells OTC supplements. In addition, we are conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an LNP encapsulated mRNA targeted for liver cancer, and (ii) SBFM-PL4, a protease inhibitor for treatment of SARS Coronavirus infections. Commercial Operations Our commercial operations are focused on the procurement of rights to pharmaceutical products for sale, currently in Canada and ultimately around the world.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 37M | 35M | 24M | - | - | - |
| Net Income | -6.0M | - | - | -27M | -12M | -2.8M |
| EPS | $5.31 | $-7.32 | $-351.36 | $-3,520.00 | $-9,520.00 | $-5,460.00 |
| Free Cash Flow | -7.4M | -14M | -8.9M | -5.4M | -1.8M | -658K |
| ROIC | -34.3% | - | - | -98.6% | -87.5% | -55.2% |
| Gross Margin | 33.0% | 30.6% | 34.6% | - | - | - |
| Debt/Equity | 0.00 | 0.30 | 0.29 | 0.35 | 8.98 | -2.71 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -6.5M | -5.8M | -4.8M | -27M | -2.4M | -577K |
| Operating Margin | -17.3% | -16.7% | -19.9% | - | - | - |
| ROE | -24.8% | - | - | -123.7% | -5875.6% | - |
| Shares Outstanding | 5M | 3M | 3M | 0M | 0M | 0M |
Sunshine Biopharma Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 32.6%.
Sunshine Biopharma Inc. (SBFM) has a 5-year average return on invested capital (ROIC) of -80.4%. This is below average and may indicate limited pricing power.
Sunshine Biopharma Inc. (SBFM) has a market capitalization of $5M. It is classified as a small-cap stock.
Sunshine Biopharma Inc. (SBFM) does not currently pay a regular dividend.
Sunshine Biopharma Inc. (SBFM) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Sunshine Biopharma Inc. (SBFM) reported annual revenue of $35 million in its most recent fiscal year, based on SEC EDGAR filings.
Sunshine Biopharma Inc. (SBFM) generated $-14 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Sunshine Biopharma Inc. (SBFM) has a debt-to-equity ratio of 0.30. This indicates a conservatively financed balance sheet.
Sunshine Biopharma Inc. (SBFM) reported earnings per share (EPS) of $-7.32 in its most recent fiscal year.
Sunshine Biopharma Inc. (SBFM) has a 5-year average gross margin of 32.6%. This indicates decent pricing power.
The Ledger Terminal provides 15 years of financial data for Sunshine Biopharma Inc. (SBFM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Sunshine Biopharma Inc. (SBFM) has a book value per share of $8.68, based on its most recent annual SEC filing.